海王生物
(000078)
| 流通市值：70.13亿 | | | 总市值：70.25亿 |
| 流通股本：26.26亿 | | | 总股本：26.31亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 14,311,503,184.96 | 7,375,593,948.22 | 30,317,288,483.53 | 24,552,692,705.95 |
| 营业收入 | 14,311,503,184.96 | 7,375,593,948.22 | 30,317,288,483.53 | 24,552,692,705.95 |
| 二、营业总成本 | 14,284,140,795.44 | 7,352,946,262.98 | 30,630,057,876.69 | 24,375,198,874.25 |
| 营业成本 | 12,979,683,425.75 | 6,694,516,270.24 | 27,444,706,675.76 | 22,121,950,620.2 |
| 税金及附加 | 38,734,701.01 | 19,088,112.54 | 98,120,147.55 | 70,567,336.46 |
| 销售费用 | 512,965,617.44 | 264,498,142.33 | 1,189,505,671.77 | 852,773,520.74 |
| 管理费用 | 432,070,744.08 | 213,274,433.76 | 1,053,478,185.27 | 762,836,836.89 |
| 研发费用 | 21,672,884.43 | 11,250,327.04 | 37,965,110.19 | 32,134,928.15 |
| 财务费用 | 299,013,422.73 | 150,318,977.07 | 806,282,086.15 | 534,935,631.81 |
| 其中:利息费用 | 297,658,906.22 | 147,116,274.87 | 808,767,253.27 | 549,294,606.07 |
| 其中:利息收入 | 15,689,947.79 | 7,125,122.33 | 44,588,115.55 | 47,666,952.01 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 70,959.24 | 23,745.97 | 6,384,310.59 | 10,026,809.34 |
| 加:投资收益 | 88,840,372.84 | 95,295,953.6 | 11,147,013.77 | -4,706,603.43 |
| 资产处置收益 | -173,310.51 | -1,851.65 | 6,808,511.29 | 5,827,945.59 |
| 资产减值损失(新) | 2,711,648.39 | 2,966,689.8 | -518,749,186.8 | 941,215.41 |
| 信用减值损失(新) | -5,521,341.46 | -36,310,103.44 | -293,122,001.37 | 48,537,615.61 |
| 其他收益 | 13,447,646.69 | 4,682,512.85 | 37,362,845.37 | 28,873,635.32 |
| 四、营业利润 | 126,738,364.71 | 89,304,632.37 | -1,062,937,900.31 | 266,994,449.54 |
| 加:营业外收入 | 10,115,881.62 | 3,071,352.2 | 25,366,475.51 | 12,143,263.61 |
| 减:营业外支出 | 4,183,755.32 | 1,620,201.43 | 44,122,844.38 | 10,259,638.38 |
| 五、利润总额 | 132,670,491.01 | 90,755,783.14 | -1,081,694,269.18 | 268,878,074.77 |
| 减:所得税费用 | 67,847,587.28 | 37,800,184.54 | 85,616,931.85 | 143,032,719.25 |
| 六、净利润 | 64,822,903.73 | 52,955,598.6 | -1,167,311,201.03 | 125,845,355.52 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 64,822,903.73 | 52,955,598.6 | -1,167,311,201.03 | 125,845,355.52 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 31,681,707.71 | 23,715,783.03 | -1,193,414,955.25 | 46,217,326.63 |
| 少数股东损益 | 33,141,196.02 | 29,239,815.57 | 26,103,754.22 | 79,628,028.89 |
| 扣除非经常损益后的净利润 | -70,526,104.47 | -74,743,595.07 | -1,237,948,388.86 | 19,735,332.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0.01 | -0.45 | 0.02 |
| (二)稀释每股收益 | 0.01 | 0.01 | -0.45 | 0.02 |
| 八、其他综合收益 | - | - | -23,500,000 | -790,000 |
| 归属于母公司股东的其他综合收益 | - | - | -23,500,000 | -790,000 |
| 九、综合收益总额 | 64,822,903.73 | 52,955,598.6 | -1,190,811,201.03 | 125,055,355.52 |
| 归属于母公司股东的综合收益总额 | 31,681,707.71 | 23,715,783.03 | -1,216,914,955.25 | 45,427,326.63 |
| 归属于少数股东的综合收益总额 | 33,141,196.02 | 29,239,815.57 | 26,103,754.22 | 79,628,028.89 |
| 公告日期 | 2025-08-30 | 2025-04-29 | 2025-04-29 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |